Skip to Content

Clinical Trials Detail

Randomized, multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)

Objective
This is a clinical trial of ipilimumab or placebo that will be administered by IV which is investigational combined with standard chemotherapy that will be administered by IV.
IRB Protocol Number
12-1364
Principal Investigator(s)
ROBERT DOEBELE

Cancer Trials

  • Lung Cancer
Sponsor(s)
Bristol Meyers
Contact
AMY BROWN at 720-848-0603
or AMY.M.BROWN@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last as long as your cancer is not progressing, and you are not experiencing any unacceptable side effects. A follow up period will consist of phone contact, physician contact, and clinic visits. // Eligibility criteria include but are not limited to 18 years or older with extensive-stage disease small cell lung cancer (ED-SCLC). .